These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6114891)

  • 1. Effects of somatostatin added to insulin in a glucose-controlled insulin infusion system.
    Selam JL; Chenon D; Pham TC; Gagnol JP; Sany C; Thomas N; Gravagne G; Orsetti A; Mirouze J
    Diabetologia; 1981 Aug; 21(2):126-30. PubMed ID: 6114891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.
    Wahren J
    Lancet; 1976 Dec; 2(7997):1213-6. PubMed ID: 63040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
    Neuhaus C; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.
    Gerich JE; Schultz TA; Lewis SB; Karam JH
    Diabetologia; 1977 Sep; 13(5):537-44. PubMed ID: 908478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus.
    Ward FR; Leblanc H; Yen SS
    J Clin Endocrinol Metab; 1975 Sep; 41(3):527-32. PubMed ID: 1159060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic action of somatostatin after oral glucose loading: due to suppression of glucagon and growth hormone or of intestinal carbohydrate absorption?
    Bratusch-Marrain P; Vierhapper H; Grubeck-Loebenstein B; Waldhäusl W; Nowotny P
    Horm Metab Res; 1981 Jun; 13(6):305-9. PubMed ID: 6114914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
    Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ
    Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 24-hour studies of the effects of somatostatin on the levels of plasma growth hormone, glucagon, and glucose in normal subjects and juvenile diabetics.
    Christensen SE; Hansen AP; Weeke J; Lundbaek K
    Diabetes; 1978 Mar; 27(3):300-6. PubMed ID: 640235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
    Basu R; Basu A; Nielsen M; Shah P; Rizza RA
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2314-9. PubMed ID: 10404795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin in maturity-onset diabetes.
    Christensen SE; Hansen AP; Lundbaek K
    Diabetes; 1978 Oct; 27(10):1013-9. PubMed ID: 700257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of daily insulin requirements in diabetics with an artificial endocrine pancreas.
    Lambert AE; Buysschaert M; Lambotte L
    Horm Metab Res Suppl; 1979; (8):120-7. PubMed ID: 395067
    [No Abstract]   [Full Text] [Related]  

  • 12. The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas).
    Nosadini R; Noy GA; Nattrass M; Alberti KG; Johnston DG; Home PD; Orskov H
    Diabetologia; 1982 Sep; 23(3):220-8. PubMed ID: 6751902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal blood sugar control in labile diabetics using a portable open-loop insulin infusion system with a flexible program.
    Froesch ER; Blatter G; Morell B
    Horm Metab Res Suppl; 1979; (8):198-201. PubMed ID: 395079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of somatostatin to correct manifest diabetic ketoacidosis.
    Lundbaek K; Hansen AP; Orskov H; Christensen SE; Iversen J; Seyer-Hansen K; Alberti KG; Whitefoot R
    Lancet; 1976 Jan; 1(7953):215-8. PubMed ID: 55530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.
    Dimitriadis G; Tessari P; Gerich J
    Metabolism; 1983 Oct; 32(10):987-92. PubMed ID: 6136893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic studies during normoglycaemic clamping of insulin-dependent diabetics using a glucose-controlled insulin infusion system.
    Nattrass M; Alberti KG; Buckle AL; Cluett B; Jaspan JB; Noy GA; Stubbs WA; Walton R
    Horm Metab Res Suppl; 1979; (8):86-92. PubMed ID: 395096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of somatostatin in maturity-onset diabetes.
    Tamborlane WV; Sherwin RS; Hendler R; Felig P
    N Engl J Med; 1977 Jul; 297(4):181-3. PubMed ID: 876274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overnight basal insulin requirements in fasting insulin-dependent diabetics.
    Clarke WL; Haymond MW; Santiago JV
    Diabetes; 1980 Jan; 29(1):78-80. PubMed ID: 6991318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
    Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.